BPH, 5-ARIs, PSA, and risk for prostate cancer diagnosis

It will come as no surprise to the well-informed that if you are taking a 5-alpha-reductase inhibitor (a 5-ARI) like dutasteride or finasteride for benign prostatic hyperplasia (BPH), it significantly lowers your “normal” PSA level (to about half the actual value). … READ MORE …

Abiraterone acetate + dutasteride in treatment of mCRPC

Does adding dutasteride (Avodart) to abiraterone acetate (Zytiga) make any difference in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC)? There is no clear answer to this question from a small, Phase II, pilot study, the results of which have just been published in Clinical Cancer Research. … READ MORE …

Reduction in prostate size prior to permanent seed prostate brachytherapy

Data from a randomized clinical trial have shown that there is more than one way to reduce the size of a man’s prostate (if such cytoreduction is needed) prior to treatment with permanent, radioactive pellets (permanent, low-dose brachytherapy) for localized prostate cancer. … READ MORE …

IADT, dutasteride, and the AVIAS trial — not the result some would want to hear

So the initial results of the AVIAS trial are not going to make a couple of our regular readers too happy — although at least a trial of the type they have been asking for has now been carried out. … READ MORE …

Swedish data support PCPT re-analysis: no increase in high-risk prostate cancer after use of 5-ARIs

Another study, just published in the British Medical Journal, appears to further debunk the idea that use of 5α-reductase inhibitors (5-ARIs) is associated with a significant increase in risk for development of high-grade prostate cancer. … READ MORE …

5-ARIs and prostate cancer risk: one step forward; one step back

As is so often the case in medicine, data suggesting a positive finding from one study comes out at about the same time as data demonstrating exactly the opposite … and in prostate cancer this occurs all too frequently! … READ MORE …

Dutasteride in the “off-therapy” cycles of ADT

A poster at the Genitourinary Cancers Symposium yesterday will bring joy to Chuck Maack’s heart. It addressed the use of dutasteride in the off-therapy cycles of intermittent androgen deprivation therapy (ADT). … READ MORE …